Steven Lynham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven Lynham has a total of 300 co-authors. Here are the top co-authors by number of shared publications:
- Malcolm Ward
Proteome Sciences plc, London, UK
9 shared publications - Simon Lovestone
Department of Psychiatry, University of Oxford
7 shared publications - Abdul Hye
King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK
5 shared publications - John Powell
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
4 shared publications Malcolm Ward
Proteomics Facility, Centre of Excellence for Mass Spectrometry, King's College London, London, UK
4 shared publications- Richard Killick
Centre for Healthy Brain Aging, IoPPN, King’s College London, London SE5 9RT, UK
4 shared publications
Latest Publications
- Open Access
POM121 regulates lentiviral nuclear import in a capsid-host factor-dependent manner
Lentiviruses such as human immunodeficiency virus 1 (HIV-1) access the nuclear lumen through the nuclear pore complex (NPC), a process coordinated by the interactions between the viral capsid and nucleoporins (NUPs). Here, using unbiased proteomic screens, we identified several capsid-associated NUPs, including POM121. Depletion of POM121 impaired HIV-1 infection in multiple cell lines and in primary CD4+ T cells, whereas equine infectious anaemia virus (EIAV) infection was enhanced, indicating that POM121 effect is virus-specific. A cytoplasmic carboxy-terminal fragment of POM121, containing its FG-rich region inhibited HIV-1 and a broader range of lentiviruses. Analysis of HIV-1 capsid mutants showed that physical interaction with POM121 does not predict functional dependence, as capsids retaining POM121 binding remained insensitive to its depletion. Strikingly, loss of cyclophilin A (CypA) completely abolished HIV-1 dependence on POM121, whereas depletion of CPSF6 produced only partial rescue, demonstrating that POM121 sensitivity is dictated by the broader network of capsid-host interactions. Finally, POM121 depletion impaired HIV-1 nuclear accumulation and selectively disrupted the nuclear import of other viral and cellular cargo. Together, these findings identify POM121 as a selective regulator of lentiviral nuclear entry whose functional contribution is determined by capsid and host-factor context.
Open AccessPOM121 regulates lentiviral nuclear import in a capsid-host factor-dependent manner
Lentiviruses such as human immunodeficiency virus 1 (HIV-1) access the nuclear lumen through the nuclear pore complex (NPC), a process coordinated by the interactions between the viral capsid and nucleoporins (NUPs). Here, using unbiased proteomic screens, we identified several capsid-associated NUPs, including POM121. Depletion of POM121 impaired HIV-1 infection in multiple cell lines and in primary CD4+ T cells, whereas equine infectious anaemia virus (EIAV) infection was enhanced, indicating that POM121 effect is virus-specific. A cytoplasmic carboxy-terminal fragment of POM121, containing its FG-rich region inhibited HIV-1 and a broader range of lentiviruses. Analysis of HIV-1 capsid mutants showed that physical interaction with POM121 does not predict functional dependence, as capsids retaining POM121 binding remained insensitive to its depletion. Strikingly, loss of cyclophilin A (CypA) completely abolished HIV-1 dependence on POM121, whereas depletion of CPSF6 produced only partial rescue, demonstrating that POM121 sensitivity is dictated by the broader network of capsid-host interactions. Finally, POM121 depletion impaired HIV-1 nuclear accumulation and selectively disrupted the nuclear import of other viral and cellular cargo. Together, these findings identify POM121 as a selective regulator of lentiviral nuclear entry whose functional contribution is determined by capsid and host-factor context.
- Open Access
- 1 March 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (2) , 101339
A novel nested gene Aff3ir participates in vascular remodeling by enhancing endothelial cell differentiation in mice
- 1 March 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (2) , 101339
Open AccessA novel nested gene Aff3ir participates in vascular remodeling by enhancing endothelial cell differentiation in mice
- Top Cited PapersOpen Access
- 2 February 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (3) , 307-324
Sox9 Accelerates Vascular Aging by Regulating Extracellular Matrix Composition and Stiffness
BACKGROUND: Vascular calcification and increased extracellular matrix (ECM) stiffness are hallmarks of vascular aging. Sox9 (SRY-box transcription factor 9) has been implicated in vascular smooth muscle cell (VSMC) osteo/chondrogenic conversion; however, its relationship with aging and calcification has not been studied. METHODS: Immunohistochemistry was performed on human aortic samples from young and aged patients. Young and senescent primary human VSMCs were induced to produce ECM, and Sox9 expression was manipulated using adenoviral overexpression and depletion. ECM properties were characterized using atomic force microscopy and proteomics, and VSMC phenotype on hydrogels and the ECM were examined using confocal microscopy. RESULTS: In vivo, Sox9 was not spatially associated with vascular calcification but correlated with the senescence marker p16 (cyclin-dependent kinase inhibitor 2A). In vitro Sox9 showed mechanosensitive responses with increased expression and nuclear translocation in senescent cells and on stiff matrices. Sox9 was found to regulate ECM stiffness and organization by orchestrating changes in collagen (Col) expression and reducing VSMC contractility, leading to the formation of an ECM that mirrored that of senescent cells. These ECM changes promoted phenotypic modulation of VSMCs, whereby senescent cells plated on ECM synthesized from cells depleted of Sox9 returned to a proliferative state, while proliferating cells on a matrix produced by Sox9 expressing cells showed reduced proliferation and increased DNA damage, reiterating features of senescent cells. LH3 (procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3) was identified as an Sox9 target and key regulator of ECM stiffness. LH3 is packaged into extracellular vesicles and Sox9 promotes extracellular vesicle secretion, leading to increased LH3 deposition within the ECM. CONCLUSIONS: These findings highlight the crucial role of ECM structure and composition in regulating VSMC phenotype. We identify a positive feedback cycle, whereby cellular senescence and increased ECM stiffening promote Sox9 expression, which, in turn, drives further ECM modifications to further accelerate stiffening and senescence.
- 2 February 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (3) , 307-324
Top Cited PapersOpen AccessSox9 Accelerates Vascular Aging by Regulating Extracellular Matrix Composition and Stiffness
BACKGROUND: Vascular calcification and increased extracellular matrix (ECM) stiffness are hallmarks of vascular aging. Sox9 (SRY-box transcription factor 9) has been implicated in vascular smooth muscle cell (VSMC) osteo/chondrogenic conversion; however, its relationship with aging and calcification has not been studied. METHODS: Immunohistochemistry was performed on human aortic samples from young and aged patients. Young and senescent primary human VSMCs were induced to produce ECM, and Sox9 expression was manipulated using adenoviral overexpression and depletion. ECM properties were characterized using atomic force microscopy and proteomics, and VSMC phenotype on hydrogels and the ECM were examined using confocal microscopy. RESULTS: In vivo, Sox9 was not spatially associated with vascular calcification but correlated with the senescence marker p16 (cyclin-dependent kinase inhibitor 2A). In vitro Sox9 showed mechanosensitive responses with increased expression and nuclear translocation in senescent cells and on stiff matrices. Sox9 was found to regulate ECM stiffness and organization by orchestrating changes in collagen (Col) expression and reducing VSMC contractility, leading to the formation of an ECM that mirrored that of senescent cells. These ECM changes promoted phenotypic modulation of VSMCs, whereby senescent cells plated on ECM synthesized from cells depleted of Sox9 returned to a proliferative state, while proliferating cells on a matrix produced by Sox9 expressing cells showed reduced proliferation and increased DNA damage, reiterating features of senescent cells. LH3 (procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3) was identified as an Sox9 target and key regulator of ECM stiffness. LH3 is packaged into extracellular vesicles and Sox9 promotes extracellular vesicle secretion, leading to increased LH3 deposition within the ECM. CONCLUSIONS: These findings highlight the crucial role of ECM structure and composition in regulating VSMC phenotype. We identify a positive feedback cycle, whereby cellular senescence and increased ECM stiffening promote Sox9 expression, which, in turn, drives further ECM modifications to further accelerate stiffening and senescence.
- Open Access
- 8 December 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (12) , 966-988
Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation
BACKGROUND: Pulmonary hypertension (PH) is a chronic vascular disease characterized, among other abnormalities, by hyperproliferative smooth muscle cells and a perturbed cellular redox and metabolic balance. Oxidants induce cell cycle arrest to halt proliferation; however, little is known about the redox-regulated effector proteins that mediate these processes. Here, we report a novel kinase-inhibitory disulfide bond in cyclin D-CDK4 (cyclin-dependent kinase 4) and investigate its role in cell proliferation and PH. METHODS: Oxidative modifications of cyclin D-CDK4 were detected in human pulmonary arterial smooth muscle cells and human pulmonary arterial endothelial cells. Site-directed mutagenesis, tandem mass-spectrometry, cell-based experiments, in vitro kinase activity assays, in silico structural modeling, and a novel redox-dead constitutive knock-in mouse were utilized to investigate the nature and definitively establish the importance of CDK4 cysteine modification in pulmonary vascular cell proliferation. Furthermore, the cyclin D-CDK4 oxidation was assessed in vivo in the pulmonary arteries and isolated human pulmonary arterial smooth muscle cells of patients with pulmonary arterial hypertension and in 3 preclinical models of PH. RESULTS: Cyclin D-CDK4 forms a reversible oxidant-induced heterodimeric disulfide dimer between C7/8 and C135, respectively, in cells in vitro and in pulmonary arteries in vivo to inhibit cyclin D-CDK4 kinase activity, decrease Rb (retinoblastoma) protein phosphorylation, and induce cell cycle arrest. Mutation of CDK4 C135 causes a kinase-impaired phenotype, which decreases cell proliferation rate and alleviates disease phenotype in an experimental mouse PH model, suggesting this cysteine is indispensable for cyclin D-CDK4 kinase activity. Pulmonary arteries and human pulmonary arterial smooth muscle cells from patients with pulmonary arterial hypertension display a decreased level of CDK4 disulfide, consistent with CDK4 being hyperactive in human pulmonary arterial hypertension. Furthermore, auranofin treatment, which induces the cyclin D-CDK4 disulfide, attenuates disease severity in experimental PH models by mitigating pulmonary vascular remodeling. CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH.
- 8 December 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (12) , 966-988
Open AccessCyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation
BACKGROUND: Pulmonary hypertension (PH) is a chronic vascular disease characterized, among other abnormalities, by hyperproliferative smooth muscle cells and a perturbed cellular redox and metabolic balance. Oxidants induce cell cycle arrest to halt proliferation; however, little is known about the redox-regulated effector proteins that mediate these processes. Here, we report a novel kinase-inhibitory disulfide bond in cyclin D-CDK4 (cyclin-dependent kinase 4) and investigate its role in cell proliferation and PH. METHODS: Oxidative modifications of cyclin D-CDK4 were detected in human pulmonary arterial smooth muscle cells and human pulmonary arterial endothelial cells. Site-directed mutagenesis, tandem mass-spectrometry, cell-based experiments, in vitro kinase activity assays, in silico structural modeling, and a novel redox-dead constitutive knock-in mouse were utilized to investigate the nature and definitively establish the importance of CDK4 cysteine modification in pulmonary vascular cell proliferation. Furthermore, the cyclin D-CDK4 oxidation was assessed in vivo in the pulmonary arteries and isolated human pulmonary arterial smooth muscle cells of patients with pulmonary arterial hypertension and in 3 preclinical models of PH. RESULTS: Cyclin D-CDK4 forms a reversible oxidant-induced heterodimeric disulfide dimer between C7/8 and C135, respectively, in cells in vitro and in pulmonary arteries in vivo to inhibit cyclin D-CDK4 kinase activity, decrease Rb (retinoblastoma) protein phosphorylation, and induce cell cycle arrest. Mutation of CDK4 C135 causes a kinase-impaired phenotype, which decreases cell proliferation rate and alleviates disease phenotype in an experimental mouse PH model, suggesting this cysteine is indispensable for cyclin D-CDK4 kinase activity. Pulmonary arteries and human pulmonary arterial smooth muscle cells from patients with pulmonary arterial hypertension display a decreased level of CDK4 disulfide, consistent with CDK4 being hyperactive in human pulmonary arterial hypertension. Furthermore, auranofin treatment, which induces the cyclin D-CDK4 disulfide, attenuates disease severity in experimental PH models by mitigating pulmonary vascular remodeling. CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH.
- Open Access
- 1 August 2023
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 136 (15)
UMAD1 contributes to ESCRT-III dynamic subunit turnover during cytokinetic abscission
Abscission is the final stage of cytokinesis whereby the midbody, a thin intercellular bridge, is resolved to separate the daughter cells. Cytokinetic abscission is mediated by the endosomal sorting complex required for transport (ESCRT), a conserved membrane remodelling machinery. The midbody organiser CEP55 recruits early acting ESCRT factors such as ESCRT-I and ALIX (also known as PDCD6IP), which subsequently initiate the formation of ESCRT-III polymers that sever the midbody. We now identify UMAD1 as an ESCRT-I subunit that facilitates abscission. UMAD1 selectively associates with VPS37C and VPS37B, supporting the formation of cytokinesis-specific ESCRT-I assemblies. TSG101 recruits UMAD1 to the site of midbody abscission, to stabilise the CEP55–ESCRT-I interaction. We further demonstrate that the UMAD1–ESCRT-I interaction facilitates the final step of cytokinesis. Paradoxically, UMAD1 and ALIX co-depletion has synergistic effects on abscission, whereas ESCRT-III recruitment to the midbody is not inhibited. Importantly, we find that both UMAD1 and ALIX are required for the dynamic exchange of ESCRT-III subunits at the midbody. Therefore, UMAD1 reveals a key functional connection between ESCRT-I and ESCRT-III that is required for cytokinesis.
- 1 August 2023
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 136 (15)
Open AccessUMAD1 contributes to ESCRT-III dynamic subunit turnover during cytokinetic abscission
Abscission is the final stage of cytokinesis whereby the midbody, a thin intercellular bridge, is resolved to separate the daughter cells. Cytokinetic abscission is mediated by the endosomal sorting complex required for transport (ESCRT), a conserved membrane remodelling machinery. The midbody organiser CEP55 recruits early acting ESCRT factors such as ESCRT-I and ALIX (also known as PDCD6IP), which subsequently initiate the formation of ESCRT-III polymers that sever the midbody. We now identify UMAD1 as an ESCRT-I subunit that facilitates abscission. UMAD1 selectively associates with VPS37C and VPS37B, supporting the formation of cytokinesis-specific ESCRT-I assemblies. TSG101 recruits UMAD1 to the site of midbody abscission, to stabilise the CEP55–ESCRT-I interaction. We further demonstrate that the UMAD1–ESCRT-I interaction facilitates the final step of cytokinesis. Paradoxically, UMAD1 and ALIX co-depletion has synergistic effects on abscission, whereas ESCRT-III recruitment to the midbody is not inhibited. Importantly, we find that both UMAD1 and ALIX are required for the dynamic exchange of ESCRT-III subunits at the midbody. Therefore, UMAD1 reveals a key functional connection between ESCRT-I and ESCRT-III that is required for cytokinesis.
- Open Access
GSK3 and Lamellipodin balance lamellipodial protrusions and focal adhesion maturation in mouse neural crest migration
Neural crest cells are multipotent cells that delaminate from the neuroepithelium, migrating to distant destinations throughout the embryo. Aberrant migration has severe consequences, such as congenital disorders. While animal models have improved our understanding of neural crest anomalies, the in vivo contributions of actin-based protrusions are still poorly understood. Here, we demonstrate that murine neural crest cells use lamellipodia and filopodia in vivo. Using neural crest-specific knockouts or inhibitors, we show that the serine-threonine kinase, Glycogen Synthase Kinase-3 (GSK3), and the cytoskeletal regulator, Lamellipodin (Lpd), are required for lamellipodia formation whilst preventing focal adhesion maturation. We consequently identified Lpd as a novel substrate of GSK3 and found that phosphorylation of Lpd favours Lpd interactions with the Scar/WAVE complex (lamellipodia formation) at the expense of Ena/VASP protein interactions (adhesion maturation and filopodia formation). All together, we provide an improved understanding of cytoskeletal regulation in mammalian neural crest migration, which has general implications for neural crest anomalies and cancer.
Open AccessGSK3 and Lamellipodin balance lamellipodial protrusions and focal adhesion maturation in mouse neural crest migration
Neural crest cells are multipotent cells that delaminate from the neuroepithelium, migrating to distant destinations throughout the embryo. Aberrant migration has severe consequences, such as congenital disorders. While animal models have improved our understanding of neural crest anomalies, the in vivo contributions of actin-based protrusions are still poorly understood. Here, we demonstrate that murine neural crest cells use lamellipodia and filopodia in vivo. Using neural crest-specific knockouts or inhibitors, we show that the serine-threonine kinase, Glycogen Synthase Kinase-3 (GSK3), and the cytoskeletal regulator, Lamellipodin (Lpd), are required for lamellipodia formation whilst preventing focal adhesion maturation. We consequently identified Lpd as a novel substrate of GSK3 and found that phosphorylation of Lpd favours Lpd interactions with the Scar/WAVE complex (lamellipodia formation) at the expense of Ena/VASP protein interactions (adhesion maturation and filopodia formation). All together, we provide an improved understanding of cytoskeletal regulation in mammalian neural crest migration, which has general implications for neural crest anomalies and cancer.
- Open Access
MX2 viral substrate breadth and inhibitory activity are regulated by protein phosphorylation
Human immunodeficiency virus type-1 (HIV-1) infection is potently inhibited by human myxovirus resistance 2 (MX2/MxB), which binds to the viral capsid and blocks the nuclear import of viral DNA. We have recently shown that phosphorylation is a key regulator of MX2 antiviral activity, with phosphorylation of serine residues at positions 14, 17 and 18 repressing MX2 function. Here, we extend the study of MX2 post-translational modifications, and identify serine and threonine phosphorylation in all domains of MX2. By substituting these residues with aspartic acid or alanine, hence mimicking the presence or absence of a phosphate group, respectively, we identified key positions that control MX2 antiviral activity. Aspartic acid substitutions of residues Ser306 or Thr334 and alanine substitutions of Thr343 yielded proteins with substantially reduced antiviral activity, whereas the presence of aspartic acid at positions Ser28, Thr151 or Thr343 resulted in enhanced activity: referred to as hypermorphic mutants. In some cases, these hypermorphic mutations, particularly when paired with other MX2 mutations (e.g., S28D/T151D or T151D/T343A) acquired the capacity to inhibit HIV-1 Capsid mutants known to be insensitive to wild type MX2, such as P90A or T210K, as well as MX2-resistant retroviruses such as equine infectious anaemia virus (EIAV) and murine leukaemia virus (MLV). This work highlights the complexity and importance of MX2 phosphorylation in the regulation of antiviral activity, and in the selection of susceptible viral substrates. Author summary Productive infection by human immunodeficiency virus type-1 (HIV-1) requires the import of viral replication complexes into the nuclei of infected cells. Myxovirus resistance 2 (MX2/MxB) blocks this step, halting nuclear accumulation of viral DNA and virus replication. We recently demonstrated how phosphorylation of a stretch of three serines in the amino-terminal domain of MX2 inhibits the antiviral activity. Here, we identify additional positions in MX2 whose phosphorylation status reduces or enhances antiviral function (hypomorphic and hypermorphic variants, respectively). Importantly, hypermorphic mutant proteins not only increased inhibitory activity against wild type HIV-1, but can also exhibit antiviral capabilities against HIV-1 Capsid mutant viruses that are resistant to wild type MX2. Furthermore, some of these proteins were also able to inhibit retroviruses that are insensitive to MX2. Therefore, we propose that phosphorylation comprises a major element of MX2 regulation and substrate determination.
Open AccessMX2 viral substrate breadth and inhibitory activity are regulated by protein phosphorylation
Human immunodeficiency virus type-1 (HIV-1) infection is potently inhibited by human myxovirus resistance 2 (MX2/MxB), which binds to the viral capsid and blocks the nuclear import of viral DNA. We have recently shown that phosphorylation is a key regulator of MX2 antiviral activity, with phosphorylation of serine residues at positions 14, 17 and 18 repressing MX2 function. Here, we extend the study of MX2 post-translational modifications, and identify serine and threonine phosphorylation in all domains of MX2. By substituting these residues with aspartic acid or alanine, hence mimicking the presence or absence of a phosphate group, respectively, we identified key positions that control MX2 antiviral activity. Aspartic acid substitutions of residues Ser306 or Thr334 and alanine substitutions of Thr343 yielded proteins with substantially reduced antiviral activity, whereas the presence of aspartic acid at positions Ser28, Thr151 or Thr343 resulted in enhanced activity: referred to as hypermorphic mutants. In some cases, these hypermorphic mutations, particularly when paired with other MX2 mutations (e.g., S28D/T151D or T151D/T343A) acquired the capacity to inhibit HIV-1 Capsid mutants known to be insensitive to wild type MX2, such as P90A or T210K, as well as MX2-resistant retroviruses such as equine infectious anaemia virus (EIAV) and murine leukaemia virus (MLV). This work highlights the complexity and importance of MX2 phosphorylation in the regulation of antiviral activity, and in the selection of susceptible viral substrates. Author summary Productive infection by human immunodeficiency virus type-1 (HIV-1) requires the import of viral replication complexes into the nuclei of infected cells. Myxovirus resistance 2 (MX2/MxB) blocks this step, halting nuclear accumulation of viral DNA and virus replication. We recently demonstrated how phosphorylation of a stretch of three serines in the amino-terminal domain of MX2 inhibits the antiviral activity. Here, we identify additional positions in MX2 whose phosphorylation status reduces or enhances antiviral function (hypomorphic and hypermorphic variants, respectively). Importantly, hypermorphic mutant proteins not only increased inhibitory activity against wild type HIV-1, but can also exhibit antiviral capabilities against HIV-1 Capsid mutant viruses that are resistant to wild type MX2. Furthermore, some of these proteins were also able to inhibit retroviruses that are insensitive to MX2. Therefore, we propose that phosphorylation comprises a major element of MX2 regulation and substrate determination.
- Open Access
- 17 August 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (8) , 1298
A Novel Immunoassay for Malondialdehyde-Conjugated Low-Density Lipoprotein Measures Dynamic Changes in the Blood of Patients Undergoing Coronary Artery Bypass Graft Surgery
Oxidized low-density lipoproteins play an important role in tissue pathology. In this study, we report a sensitive novel enzyme-linked immunosorbent assay for the detection of malondialdehyde-modified low-density lipoprotein (MDA-LDL), a key component of oxidized LDL. The assay is capable of measuring a variable presence of MDA-LDL within human plasma and serum. We demonstrate the robust nature of the assay on samples stored for over 20 months, as well as high inter-operator reproducibility (r = 0.74, p < 0.0001). The assay was capable of detecting dynamic changes in patient blood samples after coronary artery bypass graft surgery, indicating synthesis or release of MDA-LDL with the oxidative stress of surgery, followed by homeostatic clearance. This robust, sensitive and specific assay for circulating MDA-LDL will serve as a valuable translational tool for the improved detection of oxidative forms of LDL in response to a range of physiological or pathological stimuli, with potential clinical applicability.
- 17 August 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (8) , 1298
Open AccessA Novel Immunoassay for Malondialdehyde-Conjugated Low-Density Lipoprotein Measures Dynamic Changes in the Blood of Patients Undergoing Coronary Artery Bypass Graft Surgery
Oxidized low-density lipoproteins play an important role in tissue pathology. In this study, we report a sensitive novel enzyme-linked immunosorbent assay for the detection of malondialdehyde-modified low-density lipoprotein (MDA-LDL), a key component of oxidized LDL. The assay is capable of measuring a variable presence of MDA-LDL within human plasma and serum. We demonstrate the robust nature of the assay on samples stored for over 20 months, as well as high inter-operator reproducibility (r = 0.74, p < 0.0001). The assay was capable of detecting dynamic changes in patient blood samples after coronary artery bypass graft surgery, indicating synthesis or release of MDA-LDL with the oxidative stress of surgery, followed by homeostatic clearance. This robust, sensitive and specific assay for circulating MDA-LDL will serve as a valuable translational tool for the improved detection of oxidative forms of LDL in response to a range of physiological or pathological stimuli, with potential clinical applicability.
- Open Access
Identification of Chlorophyll a-b Binding Protein AB96 as a novel TGFβ1 binding agent
The discovery of compounds and proteins from plants has greatly contributed to modern medicine, especially in malaria where both quinine and artemisinin have been the cornerstone of therapeutics. Here we describe the first known plant-derived cytokine binding agent. Chlorophyll a-b binding protein AB96, present to varying levels in the leaves of all chlorophyll-containing plants, binds to active TGFβ1. Active TGFβ1 contributes to the pathology of many infectious and neoplastic diseases and therefore, by inhibiting these processes, chlorophyll a-b binding protein opens up new approaches with therapeutic potential.
Open AccessIdentification of Chlorophyll a-b Binding Protein AB96 as a novel TGFβ1 binding agent
The discovery of compounds and proteins from plants has greatly contributed to modern medicine, especially in malaria where both quinine and artemisinin have been the cornerstone of therapeutics. Here we describe the first known plant-derived cytokine binding agent. Chlorophyll a-b binding protein AB96, present to varying levels in the leaves of all chlorophyll-containing plants, binds to active TGFβ1. Active TGFβ1 contributes to the pathology of many infectious and neoplastic diseases and therefore, by inhibiting these processes, chlorophyll a-b binding protein opens up new approaches with therapeutic potential.
- 1 August 2019
- Published by University of Chicago Press in The Biological Bulletin
- Vol. 237 (1) , 26-35
Venom Composition Does Not Vary Greatly Between Different Nematocyst Types Isolated from the Primary Tentacles of Olindias sambaquiensis (Cnidaria: Hydrozoa)
In this quantitative proteomics study we determined the variety and relative abundance of toxins present in enriched preparations of two nematocyst types isolated from the primary tentacles of the adult medusa stage of the hydrozoan Olindias sambaquiensis. The two nematocyst types were microbasic mastigophores and microbasic euryteles, and these were recovered from the macerated tentacle tissues by using a differential centrifugation approach. Soluble protein extracts from these nematocysts were tagged with tandem mass tag isobaric labels and putative toxins identified using tandem mass spectrometry coupled with a stringent bioinformatics annotation pipeline. Astonishingly, the venom composition of the two capsule types was nearly identical, and there was also little difference in the comparative abundance of toxins between the two nematocyst preparations. This homogeneity suggested that the same toxin complement was present regardless of the penetrative ability of the nematocyst type. Predicted toxin protein families that constituted the venom closely matched those of the toxic proteome of O. sambaquiensis published four years previously, suggesting that venom composition in this species changes little over time. Retaining an array of different nematocyst types to deliver a single venom, rather than sustaining the high metabolic cost necessary to maintain a dynamically evolving venom, may be more advantageous, given the vastly different interspecific interactions that adult medusa encounter in coastal zones.
- 1 August 2019
- Published by University of Chicago Press in The Biological Bulletin
- Vol. 237 (1) , 26-35
Venom Composition Does Not Vary Greatly Between Different Nematocyst Types Isolated from the Primary Tentacles of Olindias sambaquiensis (Cnidaria: Hydrozoa)
In this quantitative proteomics study we determined the variety and relative abundance of toxins present in enriched preparations of two nematocyst types isolated from the primary tentacles of the adult medusa stage of the hydrozoan Olindias sambaquiensis. The two nematocyst types were microbasic mastigophores and microbasic euryteles, and these were recovered from the macerated tentacle tissues by using a differential centrifugation approach. Soluble protein extracts from these nematocysts were tagged with tandem mass tag isobaric labels and putative toxins identified using tandem mass spectrometry coupled with a stringent bioinformatics annotation pipeline. Astonishingly, the venom composition of the two capsule types was nearly identical, and there was also little difference in the comparative abundance of toxins between the two nematocyst preparations. This homogeneity suggested that the same toxin complement was present regardless of the penetrative ability of the nematocyst type. Predicted toxin protein families that constituted the venom closely matched those of the toxic proteome of O. sambaquiensis published four years previously, suggesting that venom composition in this species changes little over time. Retaining an array of different nematocyst types to deliver a single venom, rather than sustaining the high metabolic cost necessary to maintain a dynamically evolving venom, may be more advantageous, given the vastly different interspecific interactions that adult medusa encounter in coastal zones.